Coming Through On Precision Medicine – C4X Discovery’s IBD Test Breakthrough
PatientSeek Tool Identifies Genetic Signature For Ulcerative Colitis
“Proper medicine driven by data” is how C4X Discovery Holdings’ CEO Clive Dix sees the future now that his immuno-inflammation focused company has been able to identify IBD genetic response signatures in patients treated with vedolizumab.
